Erik Lium, PhD, Promoted to Executive Vice President of Mount Sinai Innovation PartnersJuly 03, 2018
The Mount Sinai Health System has announced Erik Lium, PhD, has been promoted to Executive Vice President of Mount Sinai Innovation Partners (MSIP). His new, expanded role will include broad responsibilities for innovation, commercialization, and entrepreneurship across the Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai.
“Mount Sinai is proud to announce the promotion of Dr. Lium, to further develop innovation across the health system which is a critical part of our success and institutional agenda,” said Kenneth L. Davis, MD, President and CEO of the Mount Sinai Health System. “MSIP serves a vital role in medicine to facilitate discoveries, and I have full confidence in Dr. Lium to lead the development of major breakthroughs in healthcare.”
More specifically, Dr. Lium will be in charge of advancing Mount Sinai’s research, educational, and public service missions through strategic partnerships with industry. He will also oversee the management, licensing, and commercialization of Mount Sinai technologies, and foster innovation and entrepreneurship within the Mount Sinai life sciences ecosystem. In this expanded role, Dr. Lium will help create economic development initiatives to evolve Mount Sinai’s innovation ecosystem, and oversee the creation and growth of the i3 Asset Accelerator, which advances the development of discoveries for licensing and commercial development.
“I’m pleased to build upon the strong momentum within Mount Sinai’s life science ecosystem. I look forward to directing our community’s passion and expertise in research, translation and commercialization to advance healthcare breakthroughs to the global patient population more quickly,” said Dr. Lium.
Under Dr. Lium’s leadership and through Mount Sinai’s expansive network of industry partnerships, and vast array of innovators in the fields of drugs, devices, diagnostics, and digital health, it has become a globally recognized leader in technology commercialization. Most recently, MSIP launched RenalytixAI, an artificial intelligence company aimed at risk-stratifying patients with advanced kidney disease, treating early-stage patients, and improving detection for at-risk populations.
Dr. Lium joined Mount Sinai as Vice President of MSIP in 2014 and was named Senior Vice President in 2016. Earlier, he held positions at the University of California, San Francisco (UCSF), including Assistant Vice Chancellor of Innovation, Technology and Alliances; UCSF Principal Investigator for the Bay Area National Science Foundation I-Corps node; and Assistant Vice Chancellor of Research. He also served as Founder and President of LabVelocity Inc., information services company focused on accelerating research and development in the life sciences.
Dr. Lium earned his PhD in Cellular, Molecular and Biophysical Studies at Columbia University and pursued post-doctoral training at UCSF.
MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, visit www.ip.mountsinai.org.